A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) [vorinostat] in Advanced Melanoma.
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs Vorinostat (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Feb 2007 Trial centre added.